Proactive Investors - Run By Investors For Investors

Holista CollTech teams with North American noodle manufacturer

Holista CollTech Ltd (ASX:HCT) will conduct joint research with Wing’s Food Products, a major North American noodle manufacturer, to develop the world’s first low-Glycemic Index (low-GI) noodles.
Holista CollTech teams with North American noodle manufacturer
Holista CollTech Ltd teams with North American noodle manufacturer

Holista Foods has developed PANATURA, a breakthrough natural formula which, when added to white flour, dramatically reduces blood sugar levels without changing the taste of the final product.

Based in Ontario and Alberta, Canada, Wing’s has supplied noodles to the North American market since 1953.

Wing’s will test Holista’s low-GI ingredient for use in noodles and Holista will provide expertise on the application of its formula.

The final product will be independently tested at GI-Labs, a nutrition research organization in Toronto, Canada.

Once validated, Wing’s and Holista Foods will enter a commercial agreement to manufacture and distribute the low-GI noodles in North America.

Holista Foods is a 51-49 joint-venture company set-up between Holista and Nadja Foods LLC.

According to market research group Statista, almost 50% of the world’s wheat is consumed as noodles, led by China and Indonesia, respectively.

In comparison, only a quarter of the world’s wheat is consumed as bread.

In 2015, the global demand for instant noodles amounted to 103.58 billion servings.

The low-GI movement is gaining traction as consumers are getting educated on making healthy food choices to tackle the global pandemic of obesity and diabetes.

View full HCT profile View Profile

Holista Colltech Ltd Timeline

Newswire
September 19 2017

Related Articles

cholesterol on a dial
September 24 2018
"The formation of ProBiotix Health and appointment of Adam Reynolds as chairman continues a successful strategy of building value in each division which is materialised by forming separate legal entities and taking them to a public listing,” said chief executive Stephen O’Hara
myLotus testing kit
October 31 2018
The launch at the Fertility Show in London at the start of November is the first step in a switch in focus brought about by new executive chairman Matthew Walls
Scientist
December 03 2018
Since September, the group's portfolio has steamed ahead with a number of new and successful clinical trials, as well as a boost from the float of one of its companies on the Nasdaq

© Proactive Investors 2018

Proactive Investors Australia PTY LTD ACN:132787654 ABN:19132787654.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use